GSK delivered a textbook case of winning the quarter and losing the narrative. Core operating profit rose 5% and core EPS beat consensus, yet shares plunged as much as 7% before settling at a 3.8% loss — the second-worst performer on the FTSE 100. The market was not grading the spreadsheet; it was pricing the trajectory. The damage came from vaccines. Arexvy, the RSV vaccine, saw sales drop 24%. Shingrix, the shingles blockbuster, fell 5%. Together these two products represent the franchise GSK built its post-consumer-health identity around, and both underperformed in a quarter where meningitis vaccines rose 12%. CEO Luke Miels, five months into the job, argued the declines reflected tough year-on-year comparisons and maintained that Arexvy still leads Pfizer's competing product on market share. The market was not persuaded. Behind the vaccine stumble sits a larger structural anxiety: the dolutegravir patent cliff. GSK's blockbuster HIV drug loses exclusivity toward the end of the decade, opening the door to generics. The company has set a £40bn annual revenue target for 2031 to outrun it, but that goal requires every new product — cancer drugs, respiratory treatments, next-generation vaccines — to perform. When the recently launched asthma drug Exdensur also disappointed analysts this quarter, the narrative of a pipeline that can replace dolutegravir took another hit. Miels is responding with a restructuring playbook: £1.9bn in annual cost savings, £2.4bn in restructuring charges, 1,200 job cuts in Belgium's vaccine operations, and leaner support functions at the London headquarters and in Poland and India. He says the company is slightly ahead of its three-year plan. The strategy is familiar — strip overhead, redirect savings to R&D, bet on the pipeline. GSK expects to begin 22 late-stage studies by year-end, and R&D spending is set to grow faster than sales. The most intriguing long-term play is Shingrix's potential pivot from a shingles vaccine to a dementia-prevention tool. Two large studies are underway — one examining reduction in dementia risk (data in 2029) and another on major adverse cardiovascular events (data in 2027). UK high street chemists are already reporting rising demand driven by early correlation data. If causation is demonstrated, Shingrix's addressable market expands dramatically. But that is a four-year bet at minimum. The £7.9bn acquisition of a US cancer specialist signals where Miels sees the growth replacement coming from, but cancer is the most competitive therapeutic area in pharma, and bolt-on acquisitions rarely transform revenue trajectories alone. GSK's quarterly turnover of £8.9bn (up 5%) shows the base business is not shrinking — HIV, cancer, and lupus drugs all performed — but that is maintenance, not the kind of growth that justifies a premium multiple. What investors are pricing in is not today's miss but the structural question: can GSK's pipeline generate enough new revenue to offset dolutegravir's decline, sustain vaccine franchise growth, and hit that £40bn target? Every quarter where Arexvy or Shingrix underperforms, or where a new launch like Exdensur disappoints, narrows the margin for error on a timeline that was already tight.
